Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 7 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

14%

1 trials in Phase 3/4

Results Transparency

50%

3 of 6 completed trials have results

Key Signals

3 with results

Enrollment Performance

Analytics

Phase 2

4(57.1%)

Phase 4

1(14.3%)

N/A

1(14.3%)

Phase 1

1(14.3%)

7Total

Phase 2(4)

Phase 4(1)

N/A(1)

Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT02946788Phase 2Completed

Open Label Photo-Documentation Study Of BPX-01 Minocycline Gel

Role: lead

NCT03667222Phase 2Unknown

Topical Minocycline Gel for Inflammatory Lesions of Papulopustular Rosacea

Role: lead

NCT03050086Phase 1Completed

Open Label Phase 2 Feasibility Study of BPX-04 Topical Minocycline Gel in Rosacea

Role: lead

NCT02676336Not ApplicableCompleted

A Randomized Double-blind, Placebo Controlled, Multi-center Study to Evaluate the Safety, Tolerability and Potential Effects of the Dietary Supplement Violet™ Molecular Iodine (I2) on Breast Health in Women With Cyclic Breast Discomfort and Tenderness

Role: lead

NCT02695446Phase 4Completed

Administration of Oral Extended Release Minocycline for Assessment of Skin and Plasma Concentrations of Minocycline

Role: lead

NCT02709096Phase 2Completed

BPX-01 Minocycline 1% Topical Gel for Reduction of Propionibacterium Acnes

Role: lead

NCT02815332Phase 2Completed

BPX-01 Minocycline Topical Gel in the Treatment of Acne Vulgaris

Role: lead

All 7 trials loaded